COPD - from biomarkers to novel therapeutic opportunities

Oral Presentation
Chairs: A. Mathioudakis (Liverpool, United Kingdom), L. Vanfleteren (Horn, Netherlands)

Circulating copeptin is associated with mortality irrespectively of exacerbation rate in stable COPD D. Stolz, T. Welte, A. Torres, R. Louis, W. Boersma, B. Milenkovic, K. Kostikas, F. Blasi, J. Aerts, G. Rohde, A. Lacoma, L. Boeck, J. Rakic, A. Scherr, M. Tamm (Basel, Switzerland; Alkmaar, Breda, Maastricht, Netherlands; Belgrad, Republic Of Serbia; Thessaloniki, Greece; Milan, Italy; Liege, Belgium; Badalona, Barcelona, Spain; Hannover, Hennigsdorf, Germany)
Pharmacogenetic and clinicopathological markers of BA-COPD (overlap syndrome) V. Belash, Z. Mironova, V. Trofimov, A. Ulitina, M. Zaraiski (Saint-Petersburg, Russian Federation)
Relationship of monocyte-derived macrophage phagocytosis to exacerbation susceptibility in stable COPD R. Singh, K. Belchamber, A. Mackay, B. Kowlessar, J. Allinson, S. Brill, G. Donaldson, P. Barnes, J. Wedzicha, L. Donnelly (London, United Kingdom)
The influence of complex ICS/LABA therapy on oxygen consumption in COPD patients Y. Feshchenko, L. Iashyna, S. Opimakh (Kiev, Ukraine)
A pilot study of CPAP therapy for excessive dynamic airway collapse during acute exacerbation of COPD Y. T. E. Kuo, K. Lau, G. Hamilton, E. Dai, P. Leong, P. Bardin (Melbourne, Australia)